Compare · GCTK vs MDLN
GCTK vs MDLN
Side-by-side comparison of GlucoTrack Inc. (GCTK) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GCTK and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 13019.5x GCTK ($3.6M).
- MDLN has been more active in the news (12 items in the past 4 weeks vs 11 for GCTK).
- MDLN has more recent analyst coverage (25 ratings vs 0 for GCTK).
- Company
- GlucoTrack Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $3.6M
- $46.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 11
- 12
- Recent ratings
- 0
- 25
GCTK
GlucoTrack Inc.
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Latest GCTK
- Lōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100
- SEC Form DEFA14A filed by GlucoTrack Inc.
- Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia
- GlucoTrack Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation
- SEC Form DEF 14A filed by GlucoTrack Inc.
- GlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack
- GlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Glucotrack Announces $5.5 Million Financing
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.